BaoLing-FuJin Biotech Announces 2025 Q4 Earnings: EPS of NT$2.22
NQ Score
57/100
N1 Content Completeness
4
AI Summary (NQ-processed)
BaoLing-FuJin Biotech Co., Ltd. (Stock Code: 1760) has released its financial results for the fourth quarter of 2025. The company reported basic earnings per share (EPS) of NT$2.22 for the quarter. Quarterly operating revenue reached NT$2.063 billion, with a net profit after tax of NT$190 million. BaoLing-FuJin continues its development in the biotechnology and medical sector.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What were BaoLing-FuJin Biotech's earnings per share in Q4 2025?
- A: BaoLing-FuJin Biotech reported basic earnings per share of NT$2.22 for the fourth quarter of 2025.
- Q: What was BaoLing-FuJin Biotech's operating revenue in Q4 2025?
- A: The company's operating revenue for the fourth quarter of 2025 was NT$2.063 billion.
- Q: What was BaoLing-FuJin Biotech's net profit after tax in Q4 2025?
- A: BaoLing-FuJin Biotech's net profit after tax for the fourth quarter of 2025 was NT$190 million.